4th Quarter - Report

PHARMATHENE, INC for PHARMATHENE, INC

Firm
Client
Income
—
Expenses
$208,877
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 21, 2009 $177,760 Replaced
4th Quarter - Report (this page) Jan 20, 2010 $208,877 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR-3293 Department of Labor, Health and Human Services and Education Appropriations Act for 2010: All provisions relating to development, acquisition and stockpilingof biodefense vaccines and therapeutics; Appropriations advocacy; BARDA funding. HHS procurement contract of recombinant anthrax vaccines. S.1649 - WMD Prevention and Preparedness Act of 2009 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines and therapeutics. Support and Funding for the Biomedical Advanced Research and Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines and therapeutics. Department of Defense Chemical- Biological Medical Systems (CBMS) funding for organophosphate bioscavenger advanced research and development.

LobbyistCovered position, as disclosed
MARK EDWARD COOKE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Bills named: S. 1649 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.